ID30439A - Benzoheterosiklus dan penggunaannya sebagai penghambat mek - Google Patents

Benzoheterosiklus dan penggunaannya sebagai penghambat mek

Info

Publication number: ID30439A
Authority: ID; Indonesia
Prior art keywords: benzoheterosiclus; mek; reserve; reserve mek
Prior art date: 1999-01-13

Application number

IDW00200101730A

Other languages

English (en)

Indonesian (id)

Inventor

S D Barrett

A J Bridges

Haile Tecle

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-13

Filing date

1999-12-21

Publication date

2001-12-06

1999-12-21 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2001-12-06 Publication of ID30439A publication Critical patent/ID30439A/id

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Oncology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Neurology (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Dermatology (AREA)

IDW00200101730A 1999-01-13 1999-12-21 Benzoheterosiklus dan penggunaannya sebagai penghambat mek ID30439A (id)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11587399P	1999-01-13	1999-01-13
US12255399P	1999-03-02	1999-03-02

Publications (1)

Publication Number	Publication Date
ID30439A true ID30439A (id)	2001-12-06

Family

ID=26813662

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IDW00200101730A ID30439A (id)	1999-01-13	1999-12-21	Benzoheterosiklus dan penggunaannya sebagai penghambat mek

Country Status (31)

Country	Link
US (1)	US6469004B1 (de)
EP (1)	EP1144385B1 (de)
JP (1)	JP4621355B2 (de)
KR (1)	KR20020002370A (de)
CN (1)	CN1177830C (de)
AP (1)	AP2001002224A0 (de)
AT (1)	ATE302193T1 (de)
AU (1)	AU2203700A (de)
BG (1)	BG105800A (de)
BR (1)	BR9916904A (de)
CA (1)	CA2355470C (de)
CZ (1)	CZ20012498A3 (de)
DE (1)	DE69926800T2 (de)
EA (1)	EA200100772A1 (de)
EE (1)	EE200100373A (de)
ES (1)	ES2247859T3 (de)
GE (1)	GEP20032922B (de)
HK (1)	HK1041697A1 (de)
HR (1)	HRP20010524A2 (de)
HU (1)	HUP0105113A3 (de)
ID (1)	ID30439A (de)
IL (1)	IL144214A0 (de)
IS (1)	IS5976A (de)
MA (1)	MA26771A1 (de)
NO (1)	NO20013452D0 (de)
NZ (1)	NZ513433A (de)
OA (1)	OA11746A (de)
SK (1)	SK9832001A3 (de)
TR (1)	TR200102030T2 (de)
WO (1)	WO2000042022A1 (de)
YU (1)	YU49401A (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1140062B1 (de) *	1999-01-07	2005-04-06	Warner-Lambert Company LLC	Behandlung von asthma anhand von mek-inhibitoren
PL352835A1 (en) *	1999-07-16	2003-09-08	Warner-Lambert Company	Method for treating chronic pain using mek inhibitors
US7030119B1 (en)	1999-07-16	2006-04-18	Warner-Lambert Company	Method for treating chronic pain using MEK inhibitors
EP1339702A1 (de)	2000-03-15	2003-09-03	Warner-Lambert Company	5-amid-substituierte diarylamine als mek inhibitoren
JP3811775B2 (ja) *	2000-07-19	2006-08-23	ワーナー−ランバートカンパニーリミティドライアビリティーカンパニー	４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
KR100984595B1 (ko)	2002-03-13	2010-09-30	어레이 바이오파마 인크.	Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
US7235537B2 (en) *	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1482944A4 (de) *	2002-03-13	2006-04-19	Array Biopharma Inc	N3 alkylierte benzimidazol-derivate als mek-hemmer
US20050004186A1 (en) *	2002-12-20	2005-01-06	Pfizer Inc	MEK inhibiting compounds
US20050049276A1 (en) *	2003-07-23	2005-03-03	Warner-Lambert Company, Llc	Imidazopyridines and triazolopyridines
ES2331246T3 (es)	2003-07-24	2009-12-28	Warner-Lambert Company Llc	Derivados de benzamidazol como inhibidores del mek.
DK1660090T3 (da)	2003-08-14	2012-12-17	Array Biopharma Inc	Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
US7501427B2 (en)	2003-08-14	2009-03-10	Array Biopharma, Inc.	Quinazoline analogs as receptor tyrosine kinase inhibitors
US7538120B2 (en)	2003-09-03	2009-05-26	Array Biopharma Inc.	Method of treating inflammatory diseases
US7144907B2 (en) *	2003-09-03	2006-12-05	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
TW200520745A (en) *	2003-09-19	2005-07-01	Chugai Pharmaceutical Co Ltd	Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
WO2005028447A1 (en)	2003-09-22	2005-03-31	S*Bio Pte Ltd	Benzimidazole derivates: preparation and pharmaceutical applications
NZ546011A (en) *	2003-10-21	2009-09-25	Warner Lambert Co	Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US7517994B2 (en) *	2003-11-19	2009-04-14	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
CN1905873A (zh)	2003-11-19	2007-01-31	阵列生物制药公司	Mek的杂环抑制剂及其使用方法
US7732616B2 (en) *	2003-11-19	2010-06-08	Array Biopharma Inc.	Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
NZ590160A (en)	2003-11-21	2012-07-27	Array Biopharma Inc	AKT protein kinase inhibitors
US7592340B2 (en)	2003-12-04	2009-09-22	Vertex Pharmaceuticals Incorporated	Quinoxalines useful as inhibitors of protein kinases
US20050171182A1 (en) *	2003-12-11	2005-08-04	Roger Briesewitz	Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
TWI361066B (en)	2004-07-26	2012-04-01	Chugai Pharmaceutical Co Ltd	5-substituted-2-phenylamino benzamides as mek inhibitors
MX2007004480A (es) *	2004-10-15	2007-05-08	Astrazeneca Ab	Quinoxalinas como inhibidores b raf.
ZA200703912B (en)	2004-10-20	2008-09-25	Serono Lab	3-arylamino pyridine derivatives
ES2405785T3 (es)	2005-05-18	2013-06-03	Array Biopharma Inc.	Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
CA2612419C (en)	2005-06-23	2017-06-13	Array Biopharma Inc.	Process for preparing benzimidazole compounds
AU2006262375A1 (en)	2005-06-23	2007-01-04	Array Biopharma Inc.	SNAr process for preparing benzimidazole compounds
US8101799B2 (en)	2005-07-21	2012-01-24	Ardea Biosciences	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
SI1934174T1 (sl)	2005-10-07	2011-08-31	Exelixis Inc	Inhibitorji MEK in postopki za njihovo uporabo
ATE446294T1 (de)	2005-11-15	2009-11-15	Array Biopharma Inc	N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
GB0601962D0 (en)	2006-01-31	2006-03-15	Ucb Sa	Therapeutic agents
JPWO2007132867A1 (ja)	2006-05-15	2009-09-24	杉本　芳一	癌の予防及び治療剤
ATE532789T1 (de)	2006-07-06	2011-11-15	Array Biopharma Inc	Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
CA2656566C (en)	2006-07-06	2014-06-17	Array Biopharma Inc.	Dihydrofuro pyrimidines as akt protein kinase inhibitors
ATE523499T1 (de)	2006-07-06	2011-09-15	Array Biopharma Inc	Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
US8063050B2 (en)	2006-07-06	2011-11-22	Array Biopharma Inc.	Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ZA200901009B (en) *	2006-08-21	2010-05-26	Genentech Inc	Aza-benzothiophenyl compounds and methods of use
ES2528797T3 (es) *	2006-08-21	2015-02-12	Genentech, Inc.	Compuestos de aza-benzotiofenilo y métodos de uso
AU2007286808B2 (en) *	2006-08-21	2012-12-06	Genentech, Inc.	Aza-benzofuranyl compounds and methods of use
RU2444524C2 (ru) *	2006-08-21	2012-03-10	Дженентек, Инк.	Азабензотиофенильные соединения и способы применения
PL2101759T3 (pl)	2006-12-14	2019-05-31	Exelixis Inc	Sposoby stosowania inhibitorów MEK
JO2985B1 (ar)	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
US20080312307A1 (en) *	2007-05-25	2008-12-18	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors
US9409886B2 (en)	2007-07-05	2016-08-09	Array Biopharma Inc.	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN101918373B (zh)	2007-07-05	2013-06-05	阵列生物制药公司	作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US8846683B2 (en)	2007-07-05	2014-09-30	Array Biopharma, Inc.	Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
WO2009006567A2 (en)	2007-07-05	2009-01-08	Array Biopharma Inc.	Pyrimidyl cyclopentanes as akt protein kinase inhibitors
JP5421925B2 (ja)	2007-12-19	2014-02-19	ジェネンテック，インコーポレイテッド	５−アニリノイミダゾピリジン及び使用の方法
EP2240455B1 (de)	2008-01-09	2012-12-26	Array Biopharma, Inc.	Hydroxylierte pyrimidyl-cyclopentane als akt-proteinkinasehemmer
ES2422733T3 (es)	2008-01-09	2013-09-13	Array Biopharma Inc	Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
HRP20160044T1 (hr)	2008-08-04	2016-02-26	Merck Patent Gmbh	Novi spojevi fenilamino izonikotinamida
US8993630B2 (en)	2008-11-10	2015-03-31	Bayer Intellectual Property Gmbh	Substituted sulphonamido phenoxybenzamides
WO2010068738A1 (en)	2008-12-10	2010-06-17	Dana-Farber Cancer Institute, Inc.	Mek mutations conferring resistance to mek inhibitors
US20120269803A1 (en)	2009-10-21	2012-10-25	Bayer Intellectual Property Gmbh	Substituted benzosulphonamides
EP2491014A1 (de)	2009-10-21	2012-08-29	Bayer Pharma Aktiengesellschaft	Substituierte halophenoxybenzamidderivate
EP2491015A1 (de)	2009-10-21	2012-08-29	Bayer Pharma Aktiengesellschaft	Substituierte benzosulfonamide
ES2576061T3 (es)	2010-02-25	2016-07-05	Dana-Farber Cancer Institute, Inc.	Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
BR112012022801B8 (pt)	2010-03-09	2019-10-29	Dana Farber Cancer Inst Inc	método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
WO2011131748A2 (en)	2010-04-21	2011-10-27	Probiodrug Ag	Novel inhibitors
WO2012055953A1 (en)	2010-10-29	2012-05-03	Bayer Pharma Aktiengesellschaft	Substituted phenoxypyridines
CN102020651B (zh)	2010-11-02	2012-07-18	北京赛林泰医药技术有限公司	6-芳基氨基吡啶酮甲酰胺mek抑制剂
RU2013148817A (ru)	2011-04-01	2015-05-10	Дженентек, Инк.	Комбинации соединений-ингибиторов акт и мек и способы их применения
WO2012135781A1 (en)	2011-04-01	2012-10-04	Genentech, Inc.	Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
EP2714037B1 (de)	2011-05-25	2016-07-13	Université Paris Descartes	Erk-inhibitoren zur verwendung bei der behandlung von spinaler muskelatrophie
ES2396764B1 (es)	2011-11-02	2013-12-19	Universidad Autónoma de Madrid	FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
CN103204825B (zh)	2012-01-17	2015-03-04	上海科州药物研发有限公司	作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
US20150141470A1 (en)	2012-05-08	2015-05-21	The Broad Institute, Inc.	Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
JP2015527874A (ja)	2012-05-31	2015-09-24	バイエルファーマアクチエンゲゼルシャフト	肝細胞癌（ｈｃｃ）患者の治療の有効な応答を決定するためのバイオマーカー
KR102204520B1 (ko)	2012-10-12	2021-01-20	엑셀리시스, 인코포레이티드	암의 치료에 사용하기 위한 화합물의 신규 제조 방법
FI3702351T3 (fi) *	2012-10-19	2024-01-24	Array Biopharma Inc	MEK-inhibiittorin käsittävä koostumus
EP3043822A1 (de)	2013-09-11	2016-07-20	The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone	Zusammensetzungen zur herstellung von kardiomyozyten
AU2015206603B9 (en)	2014-01-14	2019-07-18	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
CN104774188B (zh) *	2014-01-15	2019-10-11	江苏恒瑞医药股份有限公司	苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用
CN105384754B (zh) *	2014-09-02	2018-04-20	上海科州药物研发有限公司	作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CA2963091A1 (en)	2014-10-06	2016-04-14	Dana-Farber Cancer Institute, Inc.	Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
MA41866A (fr)	2015-03-31	2018-02-06	Massachusetts Gen Hospital	Molécules à auto-assemblage pour l'administration ciblée de médicaments
WO2017033113A1 (en)	2015-08-21	2017-03-02	Acerta Pharma B.V.	Therapeutic combinations of a mek inhibitor and a btk inhibitor
AU2016370846B2 (en) *	2015-12-18	2022-08-25	Ignyta, Inc.	Combinations for the treatment of cancer
AR108257A1 (es)	2016-05-02	2018-08-01	Mei Pharma Inc	Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
EA202192575A1 (ru)	2019-03-21	2022-01-14	Онксео	Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	对激酶抑制剂产生耐药性的癌症的治疗方法
CN118767143A (zh)	2019-12-12	2024-10-15	听治疗有限责任公司	用于预防和治疗听力损失的组合物和方法
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CN114478447B (zh) *	2020-11-13	2024-12-13	江苏恒瑞医药股份有限公司	苯并含氧环类衍生物、其制备方法及其在医药上的应用
TW202342018A (zh)	2022-03-04	2023-11-01	美商奇奈特生物製藥公司	Mek激酶抑制劑
WO2025073765A1 (en)	2023-10-03	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5525625A (en)	1995-01-24	1996-06-11	Warner-Lambert Company	2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
AU5610398A (en) *	1997-02-28	1998-09-18	Warner-Lambert Company	Method of treating or preventing septic shock by administering a mek inhibitor
US6310060B1 (en)	1998-06-24	2001-10-30	Warner-Lambert Company	2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
NZ501276A (en)	1997-07-01	2000-10-27	Warner Lambert Co	4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
JP2000204079A (ja) *	1999-01-13	2000-07-25	Warner Lambert Co	ジアリ―ルアミン

1999
- 1999-12-21 IL IL14421499A patent/IL144214A0/xx unknown
- 1999-12-21 EA EA200100772A patent/EA200100772A1/ru unknown
- 1999-12-21 KR KR1020017008822A patent/KR20020002370A/ko not_active Withdrawn
- 1999-12-21 EE EEP200100373A patent/EE200100373A/xx unknown
- 1999-12-21 EP EP99966521A patent/EP1144385B1/de not_active Expired - Lifetime
- 1999-12-21 HR HR20010524A patent/HRP20010524A2/hr not_active Application Discontinuation
- 1999-12-21 OA OA1200100180A patent/OA11746A/en unknown
- 1999-12-21 SK SK983-2001A patent/SK9832001A3/sk unknown
- 1999-12-21 HU HU0105113A patent/HUP0105113A3/hu unknown
- 1999-12-21 AU AU22037/00A patent/AU2203700A/en not_active Abandoned
- 1999-12-21 AP APAP/P/2001/002224A patent/AP2001002224A0/en unknown
- 1999-12-21 NZ NZ513433A patent/NZ513433A/en unknown
- 1999-12-21 YU YU49401A patent/YU49401A/sh unknown
- 1999-12-21 BR BR9916904-5A patent/BR9916904A/pt not_active Application Discontinuation
- 1999-12-21 HK HK02103390.8A patent/HK1041697A1/zh unknown
- 1999-12-21 GE GEAP19996050A patent/GEP20032922B/en unknown
- 1999-12-21 WO PCT/US1999/030483 patent/WO2000042022A1/en not_active Ceased
- 1999-12-21 ES ES99966521T patent/ES2247859T3/es not_active Expired - Lifetime
- 1999-12-21 AT AT99966521T patent/ATE302193T1/de not_active IP Right Cessation
- 1999-12-21 ID IDW00200101730A patent/ID30439A/id unknown
- 1999-12-21 JP JP2000593590A patent/JP4621355B2/ja not_active Expired - Fee Related
- 1999-12-21 CN CNB998156310A patent/CN1177830C/zh not_active Expired - Fee Related
- 1999-12-21 DE DE69926800T patent/DE69926800T2/de not_active Expired - Lifetime
- 1999-12-21 CZ CZ20012498A patent/CZ20012498A3/cs unknown
- 1999-12-21 TR TR2001/02030T patent/TR200102030T2/xx unknown
- 1999-12-21 CA CA002355470A patent/CA2355470C/en not_active Expired - Fee Related
2000
- 2000-12-21 US US09/889,059 patent/US6469004B1/en not_active Expired - Fee Related
2001
- 2001-06-22 IS IS5976A patent/IS5976A/is unknown
- 2001-07-12 NO NO20013452A patent/NO20013452D0/no not_active Application Discontinuation
- 2001-08-09 BG BG105800A patent/BG105800A/xx unknown
- 2001-08-10 MA MA26293A patent/MA26771A1/fr unknown

Also Published As

Publication number	Publication date
EA200100772A1 (ru)	2002-02-28
YU49401A (sh)	2004-07-15
AU2203700A (en)	2000-08-01
OA11746A (en)	2005-05-13
NZ513433A (en)	2003-05-30
CZ20012498A3 (cs)	2002-08-14
HUP0105113A3 (en)	2004-11-29
ES2247859T3 (es)	2006-03-01
BG105800A (en)	2002-03-29
AP2001002224A0 (en)	2001-09-30
SK9832001A3 (en)	2003-02-04
IS5976A (is)	2001-06-22
MA26771A1 (fr)	2004-12-20
IL144214A0 (en)	2002-05-23
HRP20010524A2 (en)	2002-08-31
KR20020002370A (ko)	2002-01-09
CA2355470C (en)	2008-09-30
BR9916904A (pt)	2001-10-30
NO20013452L (no)	2001-07-12
EP1144385B1 (de)	2005-08-17
JP4621355B2 (ja)	2011-01-26
WO2000042022A1 (en)	2000-07-20
NO20013452D0 (no)	2001-07-12
JP2002534510A (ja)	2002-10-15
DE69926800D1 (de)	2005-09-22
DE69926800T2 (de)	2006-05-18
EE200100373A (et)	2002-10-15
ATE302193T1 (de)	2005-09-15
CA2355470A1 (en)	2000-07-20
CN1333754A (zh)	2002-01-30
EP1144385A1 (de)	2001-10-17
HK1041697A1 (zh)	2002-07-19
CN1177830C (zh)	2004-12-01
US6469004B1 (en)	2002-10-22
TR200102030T2 (tr)	2002-01-21
HUP0105113A2 (hu)	2002-04-29
GEP20032922B (en)	2003-03-25

Publication	Publication Date	Title
ID30439A (id)	2001-12-06	Benzoheterosiklus dan penggunaannya sebagai penghambat mek
DE69807251D1 (de)	2002-09-19	Aufwärtswandler
DE69812097D1 (de)	2003-04-17	Zahnbürste mit rippen
DE69830555D1 (de)	2005-07-21	Aufnahmekopf
FI973816A0 (fi)	1997-09-26	Polypropen med hoeg smaeltstyrka
FI971692L (fi)	1998-10-22	Uusi komposiitti ja sen käyttö
DE69939801D1 (de)	2008-12-11	Kombinierter kapazitiver aufwärts/abwärtswandler
DE69830992D1 (de)	2005-09-01	Desensibilisierende zahnpaste mit beschränkter astringenz
ID24529A (id)	2000-07-20	Turunan-turunan 9-oksima eritromisin
ID19418A (id)	1998-07-09	Penghambat metaloprotease spirosiklik
FI990195L (fi)	2000-03-30	Tyydyttymätön polyesterihartsi ja sen käyttö
DK0979087T3 (da)	2004-03-08	Analgetika-kombination
EP1210084A4 (de)	2002-11-13	Pyridomorphinane, thienomorphinane und deren verwendung
NO980373D0 (no)	1998-01-28	A/D omformingsapparat
FR2767984B1 (fr)	2005-04-29	Convertisseur analogique-numerique
NO993305L (no)	1999-09-08	Reserve fluid svivel
FR2765928B1 (fr)	2002-02-01	Embrayage unidirectionnel
FI970871A0 (fi)	1997-02-28	Hakkuriteholähde
FR2790662B1 (fr)	2001-06-08	Cotyle prothetique a pions d'ancrage
FR2751646B1 (fr)	1999-01-22	Phenoxypropanolamine a action antagoniste beta3-adrenergique
DE69830516D1 (de)	2005-07-14	Copolyester objekt
DE69810075D1 (de)	2003-01-23	Kran
KR970026640U (ko)	1997-07-24	히란야 모형이 부착된 모자
KR970004216U (ko)	1997-02-19	멜로디 기능이 구비된 모자
DK199900146U3 (da)	2000-07-28	Leje samt anvendelse heraf